Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery

• Status: Recruiting
• Trial end date: 2024-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery. The investigators hypothesize that among eligible individuals, at least 35% will enroll, undergo randomization, and complete the allocated treatment group.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Utah
• Treatments: Enoxaparin

Criteria

Inclusion Criteria:

• Cesarean delivery at the University of Utah Health

Exclusion Criteria:

• Contraindication to anticoagulation

• Plan for therapeutic anticoagulation

• Known renal dysfunction (creatinine clearance <30mL/minute)

• History of venous thromboembolism

• High risk thrombophilia

• Receipt of antepartum anticoagulation for >2 weeks